Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Cited by (1,003)

Items 601–700 of 1,003

1. β-Amyloid Prions and the Pathobiology of Alzheimer’s Disease
   Joel C. Watts, Stanley B. Prusiner · 2017 · Cold Spring Harbor Perspectives in Medicine
2. Imaging of cerebrovascular pathology in animal models of Alzheimer's disease
   Klohs, Jan, Rudin, Markus, Shimshek, Derya R., Beckmann, Nicolau · 2014 · Frontiers in Aging Neuroscience
3. The Evolving Biology of Microglia in Alzheimer's Disease
   Malm, Tarja M., Jay, Taylor R., Landreth, Gary E. · 2015 · Neurotherapeutics
4. Distinguishing normal brain aging from the development of Alzheimer's disease: inflammation, insulin signaling and cognition
   Paul Denver, Paula L. McClean · 2018 · Neural Regeneration Research
5. Nasal Vaccination with β -Amyloid Peptide for the Treatment of Alzheimer's Disease
   Cynthia Ann Lemere, Ruth Maron, Dennis J. Selkoe, Howard L. Weiner · 2001 · DNA and Cell Biology
6. Potential Therapeutic Strategies for Alzheimer’s Disease Targeting or Beyondβ-Amyloid: Insights from Clinical Trials
   Qiutian Jia, Yulin Deng, Hong Qing · 2014 · BioMed Research International
7. Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapies
   Michael J. Rowan, Igor V. Klyubin, Qingyong Wang, Roger Anwyl · 2005 · Biochemical Society Transactions
8. Murine models of Alzheimer's disease and their use in developing immunotherapies
   Thomas Wısnıewskı, Einar M. Sigurdsson · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
9. High mobility group box protein‐1 inhibits microglial Aβ clearance and enhances Aβ neurotoxicity
   Kazuyuki Takata, Yoshihisa Kitamura, Daiju Tsuchiya, Toshiyuki Kawasaki, Takashi Taniguchi, Shun Shimohama · 2004 · Journal of Neuroscience Research
10. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease
    Hanjun Guan, Yinxing Liu, Abigail Daily, Sara B. Police, M.-H. Kim, Salvatore Oddo, Frank M. LaFerla, James R. Pauly, Michael Paul Murphy, Louis B. Hersh · 2008 · Journal of Neuroscience Research
11. Immunological Aetiology of Major Psychiatric Disorders
    Barbara Sperner‐Unterweger · 2005 · Drugs
12. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease
    Tsuyoshi Hamaguchi, Kenjiro Ono, Masahito Yamada · 2006 · Cellular and Molecular Life Sciences
13. Gene Vaccination to Bias the Immune Response to Amyloid-β Peptide as Therapy for Alzheimer Disease
    Bao‐Xi Qu · 2004 · Archives of Neurology
14. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with Alum to Quil A adjuvant switch
    Anahit Ghochikyan, Mikayel Mkrtichyan, Irina Petrushina, Nina Movsesyan, Adrine Karapetyan, David H. Cribbs, Michael G. Agadjanyan · 2005 · Vaccine
15. Amyloid-β dimers in the absence of plaque pathology impair learning and synaptic plasticity
    Andreas Müller‐Schiffmann, Arne Herring, Laila Abdel‐Hafiz, Aisa N. Chepkova, Sandra Schäble, Diana Wedel, Anselm H. C. Horn, Heinrich Sticht, Maria A. de Souza Silva, Kurt Gottmann et al. · 2015 · Brain
16. Human stem cell–derived monocytes and microglia‐like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2
    Christel Claes, Johanna Van Den Daele, Ruben Boon, Sarah Schouteden, Alessio Vittorio Colombo, Laura Sebastián Monasor, Mark W. E. J. Fiers, Laura Ordovás, Fatemeharefeh Nami, Bernd Bohrmann et al. · 2018 · Alzheimer s & Dementia
17. Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
    David A. Loeffler · 2023 · Journal of Alzheimer s Disease Reports
18. Amyloid binding ligands as Alzheimer’s disease therapies
    Virginia M.‐Y. Lee · 2002 · Neurobiology of Aging
19. Innate immunity and brain inflammation: the key role of complement
    Karen L. Francis, Johan van Beek, Cécile Canova, Jim W. Neal, Philippe Gasque · 2003 · Expert Reviews in Molecular Medicine
20. Anti-NR1 N-terminal-domain vaccination unmasks the crucial action of tPA on NMDA-receptor-mediated toxicity and spatial memory
    Karim Benchenane, Hervé Castel, Michel Boulouard, Rose-Marie Bluthé, Mónica Fernández‐Monreal, Benoit Denis Roussel, José P. López‐Atalaya, Sabrina Butt‐Gueulle, Véronique Agin, Eric Maubert et al. · 2007 · Journal of Cell Science
21. Time course of focused ultrasound effects on β-amyloid plaque pathology in the TgCRND8 mouse model of Alzheimer’s disease
    Charissa Poon, Kairavi Shah, Chiungting Lin, Ryan Tse, Kate K. Kim, Skyler J. Mooney, Isabelle Aubert, Bojana Stefanovic, Kullervo Hynynen · 2018 · Scientific Reports
22. Microglia as a critical player in both developmental and late-life CNS pathologies
    Derecki, Noël C., Katzmarski, Natalie, Kipnis, Jonathan, Meyer-Luehmann, Melanie · 2014 · Acta Neuropathologica
23. Drugs targeting alzheimer’s disease: Some things old and some things new
    Michaelis, Mary L. · 2003 · The Journal of Pharmacology and Experimental Therapeutics
24. Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer’s pathology: Insights and therapeutic approaches from periphery
    Ullah, Rahat, Park, Tae Ju, Huang, Xu, Kim, Myeong Ok · 2021 · Ageing Research Reviews
25. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients
    Nzeera Ketter, H. Robert Brashear, Jennifer Bogert, Jianing Di, Y Miaux, Achim Gass, Derk D. Purcell, Frederik Barkhof, Henry Michael Arrighi · 2017 · Journal of Alzheimer s Disease
26. Aβ-oligomers: A potential therapeutic target for Alzheimer's disease
    Sudeshna Ghosh, Rafat Ali, Sandeep Kumar Verma · 2023 · International Journal of Biological Macromolecules
27. High-fat diet exposure induces IgG accumulation in hypothalamic microglia
    Chun‐Xia Yi, Matthias H. Tschöp, Stephen C. Woods, Susanna M. Hofmann · 2012 · Disease Models & Mechanisms
28. C1, MBL–MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation
    László Beinrohr, József Dobó, Péter Závodszky, Péter Gál · 2008 · Trends in Molecular Medicine
29. Innate immune system and inflammation in Alzheimer’s disease: From pathogenesis to treatment
    Serpente, Maria, Bonsi, Rossana, Scarpini, Elio, Galimberti, Daniela · 2014 · Neuroimmunomodulation
30. Microglia and amyloid plaque formation in Alzheimer's disease – Evidence, possible mechanisms, and future challenges
    Stefanie Fruhwürth, Henrik Zetterberg, Søren R. Paludan · 2024 · Journal of Neuroimmunology
31. Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease
    Kaj Blennow, Harald Juergen Hampel, Henrik Zetterberg · 2013 · Neuropsychopharmacology
32. Magnetic Resonance Imaging of Alzheimer's Pathology in the Brains of Living Transgenic Mice: A New Tool in Alzheimer's Disease Research
    Clifford R. Jack, Małgorzata Marjańska, Thomas M. Wengenack, Denise A. Reyes, Geoffrey L. Curran, Joseph Lin, Gregory M. Preboske, Joseph F. Poduslo, Michael Garwood · 2007 · The Neuroscientist
33. Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β
    Simon J. Henderson, Christin Andersson, Rajesh Narwal, Juliette Janson, Tom J. Goldschmidt, Paulina Appelkvist, Anna Bogstedt, Ann-Charlott Steffen, Ulrich M. Haupts, Jan Tebbe et al. · 2013 · Brain
34. Investigation of the Role of FcγR and FcRn in mAb Distribution to the Brain
    Lubna Abuqayyas, Joseph P. Balthasar · 2012 · Molecular Pharmaceutics
35. Autoimmune and inflammatory mechanisms of CNS damage
    Minesh Kapadia, Boris Šakić · 2011 · Progress in Neurobiology
36. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain
    Xiaotian T. Fang, Greta Hultqvist, Silvio R. Meier, Gunnar Antoni, Dag Sehlin, Stina Syvänen · 2018 · NeuroImage
37. Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future
    Harald Juergen Hampel, Lon S. Schneider, Ezio Giacobini, Miia Kivipelto, Shireen Sindi, Bruno Dubois, Karl Broich, Robert Nisticò, Paul S. S. Aisen, Simone Lista · 2014 · Expert Review of Neurotherapeutics
38. Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future
    Niels D. Prins, Philip Scheltens · 2013 · Alzheimer s Research & Therapy
39. β-Amyloid Protein Structure Determines the Nature of Cytokine Release From Rat Microglia
    Catharina Lindberg, Maj‐Linda B. Selenica, Anita Westlind‐Danielsson, Marianne Schultzberg · 2005 · Journal of Molecular Neuroscience
40. Inhibition of amyloid precursor protein processing by β-secretase through site-directed antibodies
    Michal Arbel, Iftach Yacoby, Beka Solomon · 2005 · Proceedings of the National Academy of Sciences
41. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
    Lozupone, Madia, Solfrizzi, Vincenzo, D’Urso, Francesca, Di Gioia, Ilaria, Sardone, Rodolfo, Dibello, Vittorio, Stallone, Roberta, Liguori, Angelo, Ciritella, Chiara, Daniele, Antonio et al. · 2020 · Expert Opinion on Emerging Drugs
42. Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice
    Suhail Rasool, Hilda Martínez‐Coria, Jessica Wu, Frank M. LaFerla, Charles G. Glabe · 2013 · Journal of Neurochemistry
43. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return?
    Francesco Panza, Vincenzo Solfrizzi, Bruno Pietro Imbimbo, Giancarlo Logroscino · 2014 · Expert Opinion on Biological Therapy
44. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease
    Tara L. Spires‐Jones, Matthew L. Mielke, Anete Rozkalne, Melanie Meyer‐Luehmann, Alix de Calignon, Brian J. Bacskai, Dale Schenk, Bradley T. Hyman · 2008 · Neurobiology of Disease
45. Surface Plasmon Resonance Binding Kinetics of Alzheimer’s Disease Amyloid β Peptide-Capturing and Plaque-Binding Monoclonal Antibodies
    Muthu Ramakrishnan, Karunya K. Kandimalla, Thomas M. Wengenack, Kyle G. Howell, Joseph F. Poduslo · 2009 · Biochemistry
46. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's β-amyloid1–42
    Terrence Town, Martina Vendrame, Anant Patel, Daniel Poetter, Anthony DelleDonne, Takashi Mori, Robert Smeed, Fiona Crawford, Thomas Klein, Jun Tan et al. · 2002 · Journal of Neuroimmunology
47. Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells
    Hope T. Beier, Christopher B. Cowan, I-Hsien Chou, James Pallikal, James E. Henry, Melodie E. Benford, Joseph B. Jackson, Theresa A. Good, Gerard L. Coté · 2007 · Plasmonics
48. Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson’s Disease
    Nataša Z. Kuštrimović, Franca Marino, Marco Cosentino · 2018 · Current Medicinal Chemistry
49. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: An overview of biology and methodology
    Tetsuya Terasaki, Sumio Ohtsuki · 2004 · NeuroRx
50. Alzheimer's Disease: Recent Advances and Future Perspectives
    Kiren K. Ubhi, Eliezer Masliah · 2012 · Journal of Alzheimer s Disease
51. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models
    Yvonne Bouter, José Sócrates López‐Noguerola, Petra Tucholla, Gabriela A. N. Crespi, Michael W. Parker, Jens Wiltfang, Luke A. Miles, Thomas A. Bayer · 2015 · Acta Neuropathologica
52. Potential of the Antibody Against cis–Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury
    Kun Ping Lu, Asami Kondo, Önder Albayram, Megan K. Herbert, Hekun Liu, Xiao Zhen Zhou · 2016 · JAMA Neurology
53. β-Amyloid Production, Aggregation, and Clearance as Targets for Therapy in Alzheimer's Disease
    Fernanda G. De Felice, Sergio Teixeira Ferreira · 2002 · Cellular and Molecular Neurobiology
54. Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
    Susann Cattepoel, Michael Hanenberg, Luka Kulic, Roger M. Nitsch · 2011 · PLoS ONE
55. Polymer–Peptide Conjugates Disassemble Amyloid β Fibrils in a Molecular-Weight Dependent Manner
    Yang Song, Edwin G. Moore, Yanshu Guo, Jeffrey S. Moore · 2017 · Journal of the American Chemical Society
56. A Review of the Current Mammalian Models of Alzheimer’s Disease and Challenges That Need to Be Overcome
    Natasha E. Mckean, Renée R. Handley, Russell G. Snell · 2021 · International Journal of Molecular Sciences
57. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders
    Howard M. Fillit, Gregory P. Hess, J. W. Hill, P. Bonnet, Christian Toso · 2009 · Neurology
58. Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease
    Shieh‐Yueh Yang, Ming‐Jang Chiu, Ta‐Fu Chen, H. E. Horng · 2017 · Neurology and Therapy
59. Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils11Edited by J. Karn
    Omar M. A. El‐Agnaf, Sidhartha Nagala, Bhroma P. PATEL, Brian Austen · 2001 · Journal of Molecular Biology
60. Innate Immunity in Alzheimer’s Disease: A Complex Affair
    Marie‐Victoire Guillot‐Sestier, Terrence Town · 2013 · CNS & Neurological Disorders - Drug Targets
61. Clinical applications of intravenous immunoglobulins in neurology
    Richard AC Hughes, Marinos C. Dalakas, David R. Cornblath, Norman Latov, Marc E. Weksler, Norman R. Relkin · 2009 · Clinical & Experimental Immunology
62. Aβ-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice
    Deborah A. Ryan, Michael A. Mastrangelo, Wade C. Narrow, Mark A. Sullivan, Howard J. Federoff, William J. Bowers · 2010 · Molecular Therapy
63. Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- d -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis
    Richard Macrez, Pauline Obiang, Maxime Gauberti, Benoit Denis Roussel, Amandine Baron, Jérôme Parcq, Frédéric Cassé, Yannick Hommet, Cyrille Orset, Véronique Agin et al. · 2011 · Stroke
64. Distribution of Amyloid Precursor Protein and Amyloid-β Immunoreactivity in DBA/2J Glaucomatous Mouse Retinas
    David Goldblum, Anna Kipfer-Kauer, Gian‐Marco Sarra, Sebastián Wolf, Béatrice E. Frueh · 2007 · Investigative Ophthalmology & Visual Science
65. Expression of Neprilysin in Skeletal Muscle Reduces Amyloid Burden in a Transgenic Mouse Model of Alzheimer Disease
    Yinxing Liu, Christa M. Studzinski, Tina L. Beckett, Hanjun Guan, Matthew A. Hersh, Michael Paul Murphy, Ronald Klein, Louis B. Hersh · 2009 · Molecular Therapy
66. Virus‐based nanoparticles as platform technologies for modern vaccines
    Karin L. Lee, Richard M. Twyman, Steven Fiering, Nicole F. Steinmetz · 2016 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
67. Molecular chaperone α-crystallin prevents detrimental effects of neuroinflammation
    J. Gunasingh Masilamoni, E. Philip Jesudason, B’joe Baben, Charles Emmanuel Jebaraj Walter, S. Dhandayuthapani, Jayakumar Rajadas · 2005 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
68. Distribution of Amyloid Precursor Protein and Amyloid-β in Ocular Hypertensive C57BL/6 Mouse Eyes
    Anna Kipfer-Kauer, Stuart J. McKinnon, Béatrice E. Frueh, David Goldblum · 2010 · Current Eye Research
69. The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles
    Alan D. Snow, Gerardo M. Castillo, Beth P. Nguyen, Paula Y. Choi, Joel A. Cummings, Judy A. Cam, Qubai Hu, Thomas P. Lake, Weihong Pan, Abba J. Kastin et al. · 2019 · Scientific Reports
70. Telomerase gene therapy ameliorates the effects of neurodegeneration associated to short telomeres in mice
    Whittemore, Kurt, Derevyanko, Aksinya, Martinez, Paula, Serrano, Rosa, Pumarola, Martí, Bosch, Fàtima, Blasco, Maria A. · 2019 · Aging
71. The contribution of biophysical and structural studies of protein self-assembly to the design of therapeutic strategies for amyloid diseases
    Nunilo Cremades, Christopher Martin Dobson · 2017 · Neurobiology of Disease
72. Engineering antibody and protein therapeutics to cross the blood–brain barrier
    Peng Zhao, Ningyan Zhang, Zhiqiang An · 2022 · Antibody Therapeutics
73. Aβ-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice
    Douglas W. Ethell, Daniel C. Shippy, Chuanhai Cao, Jennifer R. Cracchiolo, Melissa J. Runfeldt, Brett Blake, Gary W. Arendash · 2006 · Neurobiology of Disease
74. Dementia: Alzheimer pathology and vascular factors: From mutually exclusive to interaction
    Anouk G.W. van Norden, Ewoud J. van Dijk, Karlijn F. de Laat, Philip Scheltens, Marcel G.M. Olde-Rikkert, Frank‐Erik de Leeuw · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
75. Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-β peptide
    Gili Istrin, Eran Bosis, Beka Solomon · 2006 · Journal of Neuroscience Research
76. Microglial interaction with β‐amyloid: Implications for the pathogenesis of Alzheimer's disease
    Maria E. Bamberger, Gary E. Landreth · 2001 · Microscopy Research and Technique
77. Decreased serum amyloid β1–42 autoantibody levels in Alzheimer’s disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1–42 peptide
    Sylvia Brettschneider, Nils G. Morgenthaler, Stefan Johannes Teipel, Christina Fischer-Schulz, Katharina Bürger, Richard C. Dodel, Yansheng Du, Hans‐Jürgen Möller, Andreas Bergmann, Harald Juergen Hampel · 2005 · Biological Psychiatry
78. Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
    Ross Penninkilampi, Holly M. Brothers, Guy D. Eslick · 2016 · Journal of Neuroimmune Pharmacology
79. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease
    Tobias Gustavsson, Stina Syvänen, Paul O’Callaghan, Dag Sehlin · 2020 · Translational Neurodegeneration
80. Inflammation and Alzheimer disease: The good, the bad and the ugly
    Stacie C. Weninger, Bruce A. Yankner · 2001 · Nature Medicine
81. Peripheral administration of an anti-TNF-α receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-α levels and memory deficits in mice
    Eric Detrait, BĂŠnĂŠdicte Danis, Yves Lamberty, Patrik Foerch · 2014 · Neurochemistry International
82. Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans
    Cynthia Ann Lemere, Marcel Maier, Liying Jiang, Ying Peng, Timothy J. Seabrook · 2006 · Rejuvenation Research
83. Lifelong immunization with human β-amyloid (1–42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging
    M.T. Jensen, M.D. Mottin, Jennifer R. Cracchiolo, Ralph E. Leighty, Gary W. Arendash · 2004 · Neuroscience
84. Intranasal immunotherapy for the treatment of Alzheimer’s disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants
    Cynthia Ann Lemere, Edward T Spooner, Jodi F. Leverone, Chica Mori, John David Clements · 2002 · Neurobiology of Aging
85. Treatment of Alzheimer's disease: From pharmacology to a better understanding of disease pathophysiology
    Giorgio Silvestrelli, Alessia Lanari, Lucilla Parnetti, Daniele Tomassoni, Francesco Amenta · 2005 · Mechanisms of Ageing and Development
86. Active Immunization with Amyloid-β 1–42 Impairs Memory Performance through TLR2/4-Dependent Activation of the Innate Immune System
    Patrick Vollmar, Jennifer S. Kullmann, Barbara Thilo, Malte Christian Claussen, Veit Rothhammer, Hortenzia Jacobi, Johann Sellner, Stefan Nessler, Thomas Korn, Bernhard Hemmer · 2010 · The Journal of Immunology
87. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease
    Diana Ines Dominguez, Bart De Strooper · 2002 · Trends in Pharmacological Sciences
88. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease
    Laura Gasparini, Ennio Ongini, Donna M. Wilcock, David Morgan · 2005 · Brain Research Reviews
89. Glycogen Synthase Kinase‐3β: A Mediator of Inflammation in Alzheimer′s Disease?
    Jari Koıstınaho, Tarja Malm, Gundars Goldsteins · 2011 · International Journal of Alzheimer s Disease
90. Aβ42-induced Increase in Neprilysin Is Associated with Prevention of Amyloid Plaque Formation in Vivo
    M. Hasan Mohajeri, Marc Axel Wollmer, Roger M. Nitsch · 2002 · Journal of Biological Chemistry
91. Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
    Walker, Douglas, Lue, Lih-Fen · 2007 · Current Neuropharmacology
92. Antibody Capture of Soluble Aβ Does Not Reduce Cortical Aβ Amyloidosis in the PDAPP Mouse
    Peter A. Seubert, Robin Barbour, Karen Khan, Ruth N. Motter, Pearl Tang, Dora Kholodenko, Kristin Kling, Dale Schenk, Kelly Johnson‐Wood, Sally Schroeter et al. · 2008 · Neurodegenerative Diseases
93. CD36 overexpression in human brain correlates with β-amyloid deposition but not with Alzheimer's disease
    Ricciarelli, Roberta, d'Abramo, Cristina, Zingg, Jean-Marc, Giliberto, Luca, Markesbery, William, Azzi, Angelo, Marinari, Umberto M, Pronzato, Maria A, Tabaton, Massimo · 2004 · Free Radical Biology and Medicine
94. Valproic acid induces caspase 3-mediated apoptosis in microglial cells
    Mike Dragunow, J. M. Greenwood, R.E. Cameron, Pritika J. Narayan, Simon J. O’Carroll, Andree G. Pearson, Hannah M. Gibbons · 2006 · Neuroscience
95. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy
    Jing Liu, Bin Yang, Jun Ke, Wenjia Li, Wen-Chen Suen · 2016 · Drugs & Aging
96. Mathematical Modeling of Protein Misfolding Mechanisms in Neurological Diseases: A Historical Overview
    Félix Carbonell, Yasser Iturria‐Medina, Alan Charles Evans · 2018 · Frontiers in Neurology
97. Brain delivery of biologics using a cross‐species reactive transferrin receptor 1 VNAR shuttle
    Dag Sehlin, Paweł Stocki, Tobias Gustavsson, Greta Hultqvist, Frank S. Walsh, Julia Lynn Rutkowski, Stina Syvänen · 2020 · The FASEB Journal
98. Immunotherapy in Systemic Primary (AL) Amyloidosis Using Amyloid-Reactive Monoclonal Antibodies
    A. Solomon, D. Weiss, J. Wall · 2003 · Cancer Biotherapy and Radiopharmaceuticals
99. Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer's disease–related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence
    Pourbadie, Hamid Gholami, Sayyah, Mohammad, Khoshkholgh-Sima, Baharak, Choopani, Samira, Nategh, Mohsen, Motamedi, Fereshteh, Shokrgozar, Mohammad Ali · 2018 · Neurobiology of Aging
100. Low-grade peripheral inflammation affects brain pathology in the AppNL-G-Fmouse model of Alzheimer’s disease
     Junhua Xie, Nina Gorlé, Charysse Vandendriessche, Griet Van Imschoot, Elien Van Wonterghem, Caroline Van Cauwenberghe, Eef Parthoens, Evelien Van Hamme, Saskia Lippens, Lien Van Hoecke et al. · 2021 · Acta Neuropathologica Communications